Literature DB >> 16044252

Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.

Petra Feyer1, M Heinrich Seegenschmiedt, Maria Steingraeber.   

Abstract

Radiotherapy-induced nausea and vomiting (RINV) can be one of the most distressing symptoms of radiotherapy treatment, which if incompletely controlled may last for several weeks with fractionated radiotherapy and prevent completion of the planned treatment course. Current treatment guidelines recommend the use of 5-HT(3) receptor antagonists with or without corticosteroids for highly and moderately emetogenic radiotherapy, though only granisetron and ondansetron are currently indicated for RINV in most countries. Granisetron is a potent and highly selective 5-HT(3) receptor antagonist, with demonstrated efficacy in RINV in both placebo-controlled and comparative studies. In this paper the clinical experience with granisetron in RINV is reviewed, and its efficacy and safety compared with other antiemetic therapies.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16044252     DOI： 10.1007/s00520-004-0766-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  51 in total

1.  Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.

Authors:  B Abbott; C Ippoliti; J Bruton; J Neumann; R Whaley; R Champlin
Journal:  Bone Marrow Transplant       Date:  1999-02       Impact factor: 5.483

Review 2.  Aetiology and prevention of emesis induced by radiotherapy.

Authors:  P C Feyer; A L Stewart; O J Titlbach
Journal:  Support Care Cancer       Date:  1998-05       Impact factor: 3.603

3.  Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.

Authors:  E A Perez; B Lembersky; P Kaywin; L Kalman; K Yocom; C Friedman
Journal:  Cancer J Sci Am       Date:  1998 Jan-Feb

4.  Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.

Authors:  E A Perez; P Hesketh; J Sandbach; J Reeves; S Chawla; M Markman; J Hainsworth; W Bushnell; C Friedman
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

Review 5.  Influence of age on thirst and fluid intake.

Authors:  W L Kenney; P Chiu
Journal:  Med Sci Sports Exerc       Date:  2001-09       Impact factor: 5.411

6.  Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.

Authors:  T R Spitzer; C J Friedman; W Bushnell; S R Frankel; J Raschko
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

Review 7.  The concept of selectivity in 5-HT receptor research.

Authors:  I van Wijngaarden; M T Tulp; W Soudijn
Journal:  Eur J Pharmacol       Date:  1990-06-12       Impact factor: 4.432

8.  The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy.

Authors:  R Lanciano; D M Sherman; J Michalski; A J Preston; K Yocom; C Friedman
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

9.  Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis.

Authors:  Y Belkacémi; M Ozsahin; F Pène; B Rio; L Sutton; J P Laporte; E Touboul; N C Gorin; A Laugier
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-08-01       Impact factor: 7.038

10.  Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide.

Authors:  R Miralbell; P Coucke; F Behrouz; N Blazek; M Melliger; S Philipp; R Wickenhauser; S Gebhard; T Schwabb; A Rosset
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162
View more
  3 in total

1.  A prospective study of gastrointestinal radiation therapy-induced nausea and vomiting.

Authors:  Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Edward Chow
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

2.  Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.

Authors:  Toshiyuki Ikeoka; Takao Ando; Misa Imaizumi; Ikuko Ueki; Toshiro Usa; Atsushi Kawakami
Journal:  Endocrine       Date:  2014-05       Impact factor: 3.633

3.  Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.

Authors:  Petra Christine Feyer; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Rebecca A Clark-Snow; Karin Jordan
Journal:  Support Care Cancer       Date:  2010-08-10       Impact factor: 3.603
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.